NewLimit raises $435 million for liver medicine clinical trial

statnews.com

Longevity startup NewLimit secured $435 million to fund its first clinical trial for a liver medicine. The Series C funding round was led by Founders Fund and included Thrive Capital and Lilly Ventures. The company is now valued at approximately $3.1 billion. Founded in 2021 by Brian Armstrong, Blake Byers, and Jacob Kimmel, NewLimit has raised significant capital in the past year.


With a significance score of 3.1, this news ranks in the top 10% of today's 30400 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: